A long-term analysis evaluating the cost-effectiveness of biphasic insulin lispro mix 75/25 and mix 50/50 versus long-acting basal insulin analogs in the United States

Pollock RF, Curtis BH, Valentine WJ

Record Status
This is an economic evaluation that meets the criteria for inclusion on NHS EED.

Bibliographic details

DOI
10.3111/13696998.2012.675890

Indexing Status
Subject indexing assigned by NLM

MeSH
Computer Simulation; Cost-Benefit Analysis/methods; Diabetes Mellitus, Type 2/drug therapy; Female; Health Expenditures/trends; Humans; Hypoglycemic Agents/administration & dosage/economics/therapeutic use; Insulin Lispro/administration & dosage/economics/therapeutic use; Life Expectancy; Long-Term Care/economics; Male; Outcome Assessment (Health Care)/methods; Quality-Adjusted Life Years; United States

AccessionNumber
22013027367

Date bibliographic record published
01/08/2013